## I. AMENDMENTS

In the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) A method of treating systemic lupus erythmatosus in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a humanized anti-CD11a antibody which binds specifically to human CD11a I-domain, said antibody containing a heavy chain variable region comprising the amino acid sequence of (a) CDR1 (SEQ ID NO:10), CDR2 (SEQ ID NO:11) and CDR3 (SEQ ID NO:12) or (b) SEQ ID NO:5, and a light chain variable region comprising the amino acid sequence of (a) CDR1 (SEQ ID NO: 13), CDR2 (SEQ ID NO:14) and CDR3 (SEQ ID NO:15) or (b) SEQ ID NO:2.

2. (original) The method of claim 1, wherein the humanized anti-CD11a antibody has all human kappa I consensus light chain framework residues.

3. (original) The method of claim 1, wherein the humanized anti-CD11a antibody has human $V_H$ subgroup III consensus heavy chain framework residue 93H.

4. (original) The method of claim 1, wherein the humanized anti-CD11a antibody has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:2.

5. (original) The method of claim 1, wherein the humanized anti-CD11a antibody is a full length antibody.

6. (original) The method of claim 5, wherein the humanized anti-CD11a antibody is a human IgG.

7. (original) The method of claim 1, wherein the humanized anti-CD11a antibody is bound to a cytotoxic agent.

8 – 14 (cancelled)